Skip to main content

Advertisement

SpringerLink
Log in

Paclitaxel in combination with carboplatin as salvage treatment in patients with castration-resistant prostate cancer: a Hellenic oncology research group multicenter phase II study

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Introduction

To evaluate the efficacy and tolerance of biweekly paclitaxel and carboplatin combination in patients with castration-resistant prostate cancer.

Patients and methods

Patients were treated with paclitaxel at the dose of 135 mg/m2 followed by carboplatin AUC 3 on day 1 every 2 weeks in cycles of 28 days.

Results

Thirty-eight patients with castration-resistant prostate cancer were enrolled, and all of them had received frontline chemotherapy with docetaxel and prednisone, while 24 (63.2 %) had received 2 or more prior chemotherapy regimens. In an intention-to-treatment analysis, a clinical and/or biochemical response (>50 % decline) was observed in 10 patients (26.3 %; 95 % CI, 12.3–40.3 %), stable disease in 13 (34.2 %) and progressive disease in 15 (39.5 %). The median duration of response was 6.1 months (range, 1.0–9.8), the median time to tumor progression (TTP) 3.6 months (95 % CI, 2.1–5.2) and the median overall survival 9.9 months (95 % CI, 6.2–13.6). The probability for 1-year survival was 43 %. Grade 3 and 4 neutropenia was observed in three (7.9 %) and nine (23.7 %) patients, respectively.

Conclusion

The biweekly administration of paclitaxel/carboplatin regimen in patients with castration-resistant prostate cancer is an active and well-tolerated regimen which merits to be further evaluated in the context of salvage treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Oh WK, Tay MH, Huang J (2007) Is there a role for platinum chemotherapy in the treatment of patients with hormone refractory prostate cancer? Cancer 109(3):477–486

    Article  PubMed  CAS  Google Scholar 

  2. Visakorpi T, Hyytinen E, Koivisto P et al (1995) In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 9:401–406

    Article  PubMed  CAS  Google Scholar 

  3. Gregory CW, Johnson RT Jr, Mohler JL et al (2001) Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 61:2892–2898

    PubMed  CAS  Google Scholar 

  4. Taplin ME, Bubley GJ, Shuster TD et al (1995) Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 332:1393–1398

    Article  PubMed  CAS  Google Scholar 

  5. Taplin ME, Bubley GJ, Ko YJ et al (1999) Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 59:2511–2515

    PubMed  CAS  Google Scholar 

  6. Balk SP (2002) Androgen receptor as a target in androgen-independent prostate cancer. Urology 60:132–138; discussion, 138–139

    Google Scholar 

  7. Huang J, diSant’Agnese PA (2002) Neuroendocrine differentiation in prostate cancer: an overview. In: Lamberts S (ed) Advances in oncology: the expanding role of octreotide. BioScientifica Ltd., Bristol, pp 243–262

    Google Scholar 

  8. Hatem A, Jra A, Mokb T (2008) Systemic nonhormonal management of advanced prostate cancer and its likely impact on patients’ survival and quality of life. Anticancer Drugs 19:645–653

    Article  Google Scholar 

  9. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF (2008) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 26:242–245

    Article  PubMed  CAS  Google Scholar 

  10. Urakami S, Yoshino T, Kikuno N, Imai S, Honda S, Yoneda H et al (2005) Docetaxel-based chemotherapy as second-line treatment for paclitaxel-based chemotherapy resistant hormone-refractory prostate cancer: a pilot study. Urology 65:543–548

    Article  PubMed  Google Scholar 

  11. Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–1512

    Article  PubMed  CAS  Google Scholar 

  12. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513–1520

    Article  PubMed  CAS  Google Scholar 

  13. Petrylak DP (2007) New paradigms for advanced prostate cancer. Rev Urol 9(Suppl 2):S3–S12

    PubMed  Google Scholar 

  14. Beekman KW, Fleming MT, Scher HI, Slovin SF, Ishill NM, Heller G, Kelly WK (2005) Second-line chemotherapy for prostate cancer: patient characteristics and survival. Clin Prostate Cancer 4:86–90

    PubMed  CAS  Google Scholar 

  15. Cabrespine A, Guy L, Khenifar E, Curé H, Fleury J, Penault-Llorca F, Kwiatkowski F, Barthomeuf C, Chollet P, Bay JO (2006) Randomized Phase II study comparing paclitaxel and carboplatin versus mitoxantrone in patients with hormone-refractory prostate cancer. Urology 67:354–359

    Article  PubMed  Google Scholar 

  16. Papandreou CN, Daliani DD, Thall PF et al (2002) Results of a Phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol 20:3072–3080

    Article  PubMed  CAS  Google Scholar 

  17. Berry W, Friedland D, Fleagle J et al (2006) A phase II study of weekly paclitaxel/estramustine/carboplatin in hormone-refractory prostate cancer. Clin Genitourin Cancer 5:131–137

    Article  PubMed  CAS  Google Scholar 

  18. Kelly WK, Curley T, Slovin S et al (2001) Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. J Clin Oncol 19:44–53

    PubMed  CAS  Google Scholar 

  19. Urakami S, Igawa M, Kikuno N et al (2002) Combination chemotherapy with paclitaxel, estramustine and carboplatin for hormone refractory prostate cancer. J Urol 168:2444–2450

    Article  PubMed  CAS  Google Scholar 

  20. Oh WK, Hagmann E, Manola J et al (2005) A Phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer. Clin Cancer Res 11:284–289

    PubMed  CAS  Google Scholar 

  21. Oh WK, Halabi S, Kelly WK et al (2003) A Phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: cancer and Leukemia Group B 99813. Cancer 98:2592–2598

    Article  PubMed  CAS  Google Scholar 

  22. Regan MM, O’Donnell EK, Kelly WK, Halabi S, Berry W, Urakami S, Kikuno N, Oh WK (2010) Efficacy of carboplatin-taxane combinations in the management of castration resistant prostate cancer: a pooled analysis of seven prospective clinical trials. Ann Oncol 21:312–318

    Article  PubMed  CAS  Google Scholar 

  23. Calvert AH, Newell DR, Gumbrell LA et al (1989) Carboplatin dosage: prospective evaluation of a single formula based on renal function. J Clin Oncol 7:1748–1756

    PubMed  CAS  Google Scholar 

  24. Bubley GJ, Carducci M, Dahut W et al (1999) Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 17:3461–3467

    PubMed  CAS  Google Scholar 

  25. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216

    Article  PubMed  CAS  Google Scholar 

  26. De Bono JS, Oudard S, Ozguroglu M et al (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial. Lancet 376(9747):1147–1154

    Article  PubMed  Google Scholar 

  27. De Bono JS, Logothetis CJ, Fizazi K et al. (2010) Abiraterone acetate plus low-dose prednisone improves overall survival in patients with metastatic castration-resistant prostate cancer who have progressed after docetaxel-based chemotherapy: results of COU-AA-301, a randomized double-blind placebo-controlled phase III study. 35th ESMO Congress, 2010 Oct 8–12, Milan, Italy. Ann Oncol 21(Suppl 8):viii

  28. Loriot Y, Massard C, Gross-Goupil M et al (2010) The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer. Eur J Cancer 46:1770–1772

    Article  PubMed  CAS  Google Scholar 

  29. Jeske S, Tagawa ST, Olowokure O, Selzer J, Giannakakou P, Nanus DM (2010) Carboplatin plus paclitaxel therapy after docetaxel in men with metastatic castrate resistant prostate cancer. Urol Oncol 29(6):676–681 [Epub 2010 May 7]

    Google Scholar 

  30. Sella A, Yarom N, Zisman A, Kovel S (2009) Paclitaxel, estramustine and carboplatin combination chemotherapy after initial docetaxel-based chemotherapy in castration-resistant prostate cancer. Oncology 76(6):442–446 [Epub 2009 May 5]

    Google Scholar 

  31. Mathew P, DiPaola R (2007) Taxane refractory prostate cancer. J Urol 178:S36–S41

    Article  PubMed  CAS  Google Scholar 

  32. Valero V, Jones S, Von Hoff D et al (1998) A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin Oncol 16:3362–3368

    PubMed  CAS  Google Scholar 

  33. Taguchi T, Aihara T, Takatsuka Y et al (2004) Phase II study of weekly paclitaxel for docetaxel-resistant metastatic breast cancer in Japan. Breast J 10:509–513

    Article  PubMed  CAS  Google Scholar 

  34. Seidman A, Hochhauser D, Gollub M et al (1996) Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. J Clin Oncol 14:1877–1884

    PubMed  CAS  Google Scholar 

  35. Snyder JP, Nettles JH, Cornett B et al (2001) The binding conformation of taxol in β-tubulin: a model based on electron crystallographic density. Proc Natl Acad Sci U S A 98:5312–5316

    Article  PubMed  CAS  Google Scholar 

  36. Di Lorenzo G, Buonerba C, Faiella A, Rescigno P, Rizzo M, Autorino R, Perdonà S, Riccardi N, Scagliorini S, Scognamiglio F, Masala D, Ferro M, Palmieri G, Aieta M, Marinelli A, Altieri V, De Placido S, Cartenì G (2010) Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer. B J U 107:234–239

    Google Scholar 

  37. Ross RW, Beer TM, Jacobus S et al (2008) A phase II study of carboplatin plus docetaxel in men with metastatic hormone refractory prostate cancer who are refractory to docetaxel. Cancer 112:521–526

    Article  PubMed  CAS  Google Scholar 

  38. Colloca G, Venturino A, Checcaglini F (2011) Second-line chemotherapy in metastatic docetaxel-resistant prostate cancer: a review. Med Oncol [Epub ahead of print]

  39. Eymard J-C, Oudard S, Gravis G, Ferrero J-M, Theodor C, Joly F, Priou F, Krakowski I, Zannetti A, Thill L, Beuzeboc P (2010) Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel sensitive prostate cancer: a retrospective multicentre study. BJUI 106:974–978

    Article  CAS  Google Scholar 

  40. Buonerba C, Palmieri G, Di Lorenzo G (2010) Docetaxel rechallenge in castration-resistant prostate cancer: scientific legitimacy of common clinical practice. Eur Urol 58(4):636–637 [Epub 2010 Jun 23]

    Google Scholar 

  41. Nakabayashi M, Sartor O, Jacobus S et al (2008) Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer. BJU Int 101:308–312

    Article  PubMed  CAS  Google Scholar 

  42. Paller CJ, Antonarakis E, Cabazitaxel S (2011) A novel second-line treatment for metastatic castration-resistant prostate cancer. Drug Design Dev Ther 5:117–124

    CAS  Google Scholar 

  43. De Bono JS, Sartor O (2011) Cabazitaxel for castration-resistant prostate cancer—author’s reply. Lancet 377(9760):122–123

    Article  Google Scholar 

Download references

Acknowledgments

This work was partly supported by a grant from the Cretan Association for Biomedical Research (CABR).

Conflict of interest

The authors have not conflict of interest to declare.

Author information

Authors and Affiliations

  1. Department of Medical Oncology, 251 Air Force Hospital, 3, P. Kanellopoulou Str., 115 25, Athens, Greece

    N. Kentepozidis & A. Soultati

  2. Department of Medical Oncology, IASO General Hospital, Athens, Greece

    S. Giassas & N. Pantazopoulos

  3. Department of Medical Oncology, University General Hospital of Heraklion, Heraklion, Greece

    N. Vardakis, A. Kalykaki, A. Kotsakis, E. Papadimitraki, V. Bozionellou & V. Georgoulias

Authors
  1. N. Kentepozidis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Soultati
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Giassas
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. N. Vardakis
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. Kalykaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A. Kotsakis
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. E. Papadimitraki
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. N. Pantazopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. V. Bozionellou
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. V. Georgoulias
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to N. Kentepozidis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kentepozidis, N., Soultati, A., Giassas, S. et al. Paclitaxel in combination with carboplatin as salvage treatment in patients with castration-resistant prostate cancer: a Hellenic oncology research group multicenter phase II study. Cancer Chemother Pharmacol 70, 161–168 (2012). https://doi.org/10.1007/s00280-012-1896-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-012-1896-9

Keywords

Search

Navigation